GRFS Stock Analysis: Buy, Sell, or Hold?
GRFS - Grifois, S.A.
$7.16
0.08 (1.13%)
▲
5d:
-2.85%
30d:
-6.16%
90d:
-13.21%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 29, 2026
24d
Get Alerted When GRFS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GRFS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GRFS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.16
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.65
32.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GRFS is currently trading at $7.16, which is considered oversold relative to its 30-day fair value range of $7.22 to $7.76. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.0) compared to its historical average (6.1). Remarkably, the market is currently pricing in an annual earnings decline of 6.5% over the next few years. This pessimistic expectation contrasts with the company's recent 43.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GRFS is in a strong downtrend. The price is currently testing key support at $6.96. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GRFS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.87 (+51.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GRFS is in a strong downtrend. The price is currently testing key support at $6.96. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GRFS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $10.87 (+51.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.22 -
$7.76
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 51.7% below Wall St target ($10.87)
Trading Range Analysis
30-Day Trading Range
$7.22 -
$7.76
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$6.96
Resistance Level
$7.49
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
4.96
Wall Street Target
$10.87
(+51.7%)
Revenue Growth (YoY)
-4.8%
Earnings Growth (YoY)
43.5%
Profit Margin
5.6%
Valuation Discount vs History
-6.5% cheaper
PE vs Historical
5.0 vs 6.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.5%
(market-implied from PE analysis)
1-Year Target
$6.69
(-7%)
2-Year Target
$6.26
(-13%)
3-Year Target
$5.85
(-18%)
3-Yr Target (if PE normalizes)
(PE: 5→6)
$7.20
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 36.0%)
$79.19
(+1006%)
Base:
(SPY PE: 5.0, Growth: 36.0%)
$18.02
(+152%)
Bear:
(PE: 4.2, Growth: 36.0%)
$15.32
(+114%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (10x PE), but valuation improves significantly next year (5x PE) as earnings recover.
Trailing PE: 10.26 | Current EPS (TTM): $0.69
Bull Case
$15.58
(+118%)
Analyst growth 100.0%, PE expands to 11.3
Base Case
$14.16
(+98%)
Market implied 100.0%, PE stable at 10.3
Bear Case
$4.81
(-33%)
Severe decline -20.0%, PE contracts to 8.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.0 to 6.1
Stabilization Target:
$8.81
(+23.1%)
PE Expansion Potential:
+23.1%
Share & Embed Analysis
Last updated: July 04, 2026 4:13 AM ET
Data refreshes hourly during market hours. Next update: 5:13 AM
Data refreshes hourly during market hours. Next update: 5:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRFS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1223 | 61 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 67 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 69 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 67 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 60 HOLD |
